Abstract: This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II: T1-f0-g0-a1-b1-c1-d1-e1-f1-g1-a2-b2-c2-d2-e2-f2-g2-a3-b3-c3-d3-e3-T2 ??(I) T3-g?0-a?1-b?1-c?1-d?1-e?1-f?1-g?1-a?2-b?2-c?2-d?2-e?2-f?2-g?2-a?3-b?3-c?3-d?3-e?3-f?3-T4 ??(II), as described in the present application. Methods of using these macrostructures are also disclosed.
Type:
Application
Filed:
November 14, 2019
Publication date:
June 18, 2020
Inventors:
Paramjit S. ARORA, Ethel CESARMAN, Michael G. WUO, Jouliana SADEK
Abstract: Peptides and conjugates are described herein, including peptides having antimicrobial and/or anticancer properties, as are compositions, articles, and kits comprising such peptides and conjugates, and methods for using the peptides and conjugates.
Type:
Application
Filed:
December 11, 2019
Publication date:
June 18, 2020
Applicant:
George Mason Research Foundation, Inc.
Inventors:
Barney Bishop, Saswata K. Sahoo, Justin Davis
Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Sydnrome (SBS) are also described.
Type:
Application
Filed:
July 25, 2018
Publication date:
June 18, 2020
Applicant:
Saint Louis University
Inventors:
Marvin J. MEYERS, David C. WOOD, Stacy D. ARNETT, Matthew P. YATES, Peter G. RUMINSKI
Abstract: Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.
Type:
Application
Filed:
May 4, 2018
Publication date:
June 18, 2020
Inventors:
David EVELETH, Jennifer JENKINS-EVELETH, Amuthakannan SUBRAMANIAM, Ralph BRADSHAW
Abstract: A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.
Type:
Application
Filed:
June 4, 2018
Publication date:
June 18, 2020
Inventors:
Haichao Wang, Wei Li, Jianhua Li, Kevin J. Tracey
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
February 24, 2020
Publication date:
June 18, 2020
Inventors:
Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.
Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 7 and VL having the amino acid sequence of SEQ ID NO: 8. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-? in CAR-T cells in vitro and in vivo.
Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor a/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
Type:
Application
Filed:
January 22, 2020
Publication date:
June 18, 2020
Inventors:
HING C. WONG, PETER RHODE, BAI LIU, XIAOYUN ZHU, KAI-PING HAN
Abstract: The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R??(I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.
Abstract: The invention is related to the production and development of a lyophilized injectable formulation of modified antibodies or their variants, highly specific neutralizers of heterologous mixtures of proteins, peptides and other organic or inorganic components have different specific activities and may include but are not limited to the venoms of venomous animals. For convenience, we refer to venoms, but all type of venoms was included of land and marine animals. It is also addressed to the production method which includes the hyperimmunization of mammals for the production of highly specific antibodies, the modification (fragmentation) and purification process, and finally the injectable formulation conferring thereon properties of high purity and high specificity.
Type:
Application
Filed:
December 13, 2019
Publication date:
June 18, 2020
Inventors:
Juan Lopez DE SILANES PEREZ, Jesús Raúl SORIA OSORIO
Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
Type:
Application
Filed:
October 18, 2019
Publication date:
June 18, 2020
Inventors:
Johanna ABEND, Zorica DRAGIC, Adam Lloyd FEIRE, Mark KNAPP, Steven KOVACS, Elisabetta TRAGGIAI, Lichun WANG, Yongqiang WANG, Danqing WU, Qilong WU, Fangmin Xu
Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
Type:
Application
Filed:
April 25, 2018
Publication date:
June 18, 2020
Inventors:
Wei BU, Masaru KANEKIYO, Michael Gordon JOYCE, Jeffrey I. COHEN
Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
Type:
Application
Filed:
November 7, 2019
Publication date:
June 18, 2020
Inventors:
Nicole KALLEWAARD-LELAY, Qing ZHU, Ebony BENJAMIN, Leslie WACHTER, Andy YUAN, Josephine Mary MCAULIFFE, Davide CORTI, Antonio LANZAVECCHIA
Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
Type:
Application
Filed:
January 17, 2020
Publication date:
June 18, 2020
Applicant:
TRELLIS BIOSCIENCE, LLC
Inventors:
Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
Abstract: The present invention provides antibodies and antigen binding fragments thereof that bind to human Follistatin-Like-3 (FSTL3) protein, compositions comprising such antibodies, and methods of making and using such antibodies.
Abstract: The present invention relates in particular to polyclonal antibodies directed against peptides, particularly derivatives of the propeptide of sequence QDRLDAPPPPAAPLPRWSGPIGVSWGLRAAAAGGAFPRGGRW RR (SEQ ID NO 1). The present invention also relates to a method for the production of said antibodies and to a method for assaying said peptides. In addition, the present invention relates to a method for detecting/determining depression in an individual and a method for monitoring the effectiveness of a treatment for depression.
Type:
Application
Filed:
October 11, 2017
Publication date:
June 18, 2020
Inventors:
Jean MAZELLA, Marc BORSOTTO, Catherine HEURTEAUX, Morgane ROULOT
Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.
Abstract: Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.
Abstract: A method for predicting a therapeutic effect of a chemotherapy using an antitumor agent comprising an LSD1 inhibitor in a cancer patient based on an expression level of INSM1 in a sample containing tumor cells isolated from the cancer patient.
Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.
Type:
Application
Filed:
May 3, 2018
Publication date:
June 18, 2020
Inventors:
Gary Levy, Ramzi Khattar, Andrzej Chruscinski, Barbara Vanderhyden, Curtis McCloskey
Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
Type:
Application
Filed:
December 9, 2019
Publication date:
June 18, 2020
Inventors:
Kim Suzanne MIDWOOD, Philip Antony BLAND-WARD, Nigel BURNS, Patrick John HEXTALL, Susan Rebecca AUNGIER
Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
Type:
Application
Filed:
December 20, 2019
Publication date:
June 18, 2020
Inventors:
Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
Type:
Application
Filed:
December 27, 2019
Publication date:
June 18, 2020
Inventors:
Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond-linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.
Type:
Application
Filed:
August 31, 2018
Publication date:
June 18, 2020
Inventors:
Tomohiro YOSHIMOTO, Joseph M. PALUMBO, Violetta I. STONE, Torn KATO, Koubun YASUDA
Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.
Type:
Application
Filed:
December 12, 2019
Publication date:
June 18, 2020
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
Type:
Application
Filed:
November 27, 2019
Publication date:
June 18, 2020
Applicant:
Bristol-Myers Squibb Company
Inventors:
Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
Abstract: Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.
Type:
Application
Filed:
December 27, 2019
Publication date:
June 18, 2020
Inventors:
Najmia Amirina, Hareesh Chamarthi, Maria Isabel Chiu, Daniel Doty, Bin Feng, Aleksander Jonca, Thomas McQuade, Anhco Nguyen, Sheila Ranganath, Hans Albert Felix Scheuplein, Vikki A. Spaulding, Lei Wang, Jennifer Watkins-Yoon, Sri Sahitya Vadde
Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Type:
Application
Filed:
July 24, 2019
Publication date:
June 18, 2020
Inventors:
Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
Type:
Application
Filed:
May 8, 2018
Publication date:
June 18, 2020
Applicant:
Adimab, LLC
Inventors:
Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Type:
Application
Filed:
February 27, 2020
Publication date:
June 18, 2020
Inventors:
Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
Type:
Application
Filed:
December 19, 2017
Publication date:
June 18, 2020
Inventors:
Jamie Iain CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
Abstract: Provided herein are antibodies that selectively bind to Tim-3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. In addition, provided herein are bi-specific antibodies and antigen binding constructs that selectively bind to Tim-3 and/or PD-1, their isoforms and homologs, and compositions comprising the antibodies and antigen binding constructs. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
Type:
Application
Filed:
February 22, 2018
Publication date:
June 18, 2020
Inventors:
Ryan STAFFORD, Alice YAM, Stephanie ARMSTRONG, John LEE, Alexander STEINER, Junhao YANG, Christine CHENG
Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
Type:
Application
Filed:
October 11, 2019
Publication date:
June 18, 2020
Applicant:
InhibRx, Inc.
Inventors:
Rajay A. PANDIT, John C. TIMMER, Angelica N. SANABRIA, Florian SULZMAIER, Brendan P. ECKELMAN
Abstract: The present invention provides methods of treating cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of an agent directed to human ICOS and an effective amount of an agent directed to human PD1 or human PD-L1 sequentially. The present invention also provides an anti-ICOS antibody or antigen binding fragment thereof and an anti-PD1 antibody or antigen binding fragment thereof for sequential use in treating cancer in a human in need thereof. The present invention provides an anti-ICOS antibody or antigen binding fragment thereof and an anti-PD-L1 antibody or antigen binding fragment thereof for sequential use in treating cancer in a human in need thereof.
Type:
Application
Filed:
June 8, 2018
Publication date:
June 18, 2020
Inventors:
Meixia BI, Christopher B. HOPSON, Patrick A. MAYES, Sapna YADA VILLI
Abstract: The present invention provides a combination of an anti-ICOS antibody or antigen binding portion thereof and an anti-OX40 antibody or antigen binding portion thereof. The present invention also provides method of treating cancer in a patient in need thereof comprising administering to the patient an effective amount of an anti-ICOS antibody and an effective amount of an anti-OX40 antibody or antigen binding portion thereof.
Type:
Application
Filed:
June 8, 2018
Publication date:
June 18, 2020
Inventors:
Christopher B. HOPSON, David J. KILIAN, Patrick A. MAYES, Sapna YADAYILLI, Niranjan YANAMANDRA
Abstract: This document provides methods and materials for detecting B7-H1 polypeptides (e.g., soluble B7-H1 polypeptides). For example, antibodies (e.g., monoclonal antibodies) that bind to a B7-H1 polypeptide (e.g., a soluble B7-H1 polypeptide) are provided.
Type:
Application
Filed:
October 26, 2016
Publication date:
June 18, 2020
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Programmed Death Ligand-1 (PD-L1). These PD-L1 antibodies, or antigen-binding fragments thereof, have a high affinity for PD-L1, function to inhibit PD-L1, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human), are capable of increasing T-cell proliferation and IL-2 secretion in a mixed lymphocyte reaction, and can be used to treat human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).
Abstract: This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.
Type:
Application
Filed:
December 5, 2019
Publication date:
June 18, 2020
Applicant:
Bristol-Myers Squibb Company
Inventors:
Demetrios MANEKAS, Joseph GROSSO, Jeffrey A. ANDERSON
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with TrkB or TrkC agonist compositions and formulations administered to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Type:
Application
Filed:
December 23, 2019
Publication date:
June 18, 2020
Inventors:
Horacio Uri SARAGOVI, Fabrice PIU, Alan FOSTER, KristenAnn BLACK
Abstract: The present invention relates to methods and compositions for decreasing the level of PD-1 on a CD8+ T cell, converting a CD25+ Foxp3+ regulatory T cell to a CD25? Foxp3? helper-like T cell, and reprogramming subpopulations of T cells to a phenotype suitable to enhance an immunotherapy treatment using an inhibitor of CXCL12 signaling.
Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Type:
Application
Filed:
February 21, 2020
Publication date:
June 18, 2020
Inventors:
David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
Abstract: Provided herein are BAFF-R antibodies as well as compositions and methods of making and using the same. The antibodies provided herein are, inter alia, useful for the treatment of cancer and autoimmune diseases.
Type:
Application
Filed:
June 6, 2017
Publication date:
June 18, 2020
Applicants:
CITY OF HOPE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Hong QIN, Larry W. KWAK, Jingxing LI, Kexin HUANG